JP2006517568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006517568A5 JP2006517568A5 JP2006502018A JP2006502018A JP2006517568A5 JP 2006517568 A5 JP2006517568 A5 JP 2006517568A5 JP 2006502018 A JP2006502018 A JP 2006502018A JP 2006502018 A JP2006502018 A JP 2006502018A JP 2006517568 A5 JP2006517568 A5 JP 2006517568A5
- Authority
- JP
- Japan
- Prior art keywords
- aza
- bicyclo
- octane
- methyl
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000002193 Pain Diseases 0.000 claims description 11
- 206010012289 Dementia Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000019906 panic disease Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000017194 Affective disease Diseases 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 4
- 208000019022 Mood disease Diseases 0.000 claims description 4
- 206010043269 Tension headache Diseases 0.000 claims description 4
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 206010013663 drug dependence Diseases 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 208000011117 substance-related disease Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 208000000112 Myalgia Diseases 0.000 claims description 3
- 206010034912 Phobia Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 208000008035 Back Pain Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 208000032841 Bulimia Diseases 0.000 claims description 2
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
- 208000026097 Factitious disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 241000208125 Nicotiana Species 0.000 claims description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 2
- 206010057852 Nicotine dependence Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
- 206010033664 Panic attack Diseases 0.000 claims description 2
- 206010052794 Panic disorder with agoraphobia Diseases 0.000 claims description 2
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010034010 Parkinsonism Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 208000008348 Post-Concussion Syndrome Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 206010036618 Premenstrual syndrome Diseases 0.000 claims description 2
- 206010052276 Pseudodementia Diseases 0.000 claims description 2
- 206010041250 Social phobia Diseases 0.000 claims description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 2
- 208000025569 Tobacco Use disease Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims description 2
- 208000026345 acute stress disease Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 201000007930 alcohol dependence Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
- 208000025748 atypical depressive disease Diseases 0.000 claims description 2
- 208000028683 bipolar I disease Diseases 0.000 claims description 2
- 208000022257 bipolar II disease Diseases 0.000 claims description 2
- 230000006931 brain damage Effects 0.000 claims description 2
- 231100000874 brain damage Toxicity 0.000 claims description 2
- 208000029028 brain injury Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000006145 cocaine dependence Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 208000024732 dysthymic disease Diseases 0.000 claims description 2
- 210000001097 facial muscle Anatomy 0.000 claims description 2
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 2
- 201000001881 impotence Diseases 0.000 claims description 2
- 230000000938 luteal effect Effects 0.000 claims description 2
- 208000024714 major depressive disease Diseases 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 230000007074 memory dysfunction Effects 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 230000036651 mood Effects 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 206010036596 premature ejaculation Diseases 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 208000020685 sleep-wake disease Diseases 0.000 claims description 2
- 201000001716 specific phobia Diseases 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- -1 2,3-dichlorophenyl Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 3
- 208000027534 Emotional disease Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000001624 naphthyl group Chemical group 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- GBDJSNIQOSJLGD-FPGXKEGCSA-N (3r,4s)-3-(furan-2-yl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1([C@H]2[C@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CO1 GBDJSNIQOSJLGD-FPGXKEGCSA-N 0.000 claims 1
- HMSARLHRQFZWRA-IITXJAJYSA-N (3r,4s)-3-(furan-3-yl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C=1([C@H]2[C@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)C=COC=1 HMSARLHRQFZWRA-IITXJAJYSA-N 0.000 claims 1
- UXVCEUMUEPEJLI-IQXANGCESA-N (3r,4s)-4-[(2,3-dichlorophenoxy)methyl]-3-(furan-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@@H]1C2CCC(C[C@H]1C=1OC=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl UXVCEUMUEPEJLI-IQXANGCESA-N 0.000 claims 1
- IFELXXBSGKFFEI-GWUWNPHMSA-N (3r,4s)-4-[(2,3-dichlorophenoxy)methyl]-3-(furan-3-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@@H]1C2CCC(C[C@H]1C1=COC=C1)N2C)OC1=CC=CC(Cl)=C1Cl IFELXXBSGKFFEI-GWUWNPHMSA-N 0.000 claims 1
- MVJHWSQKIKGQMW-IQXANGCESA-N (3r,4s)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-3-thiophen-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C([C@@H]1C2CCC(C[C@H]1C=1SC=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl MVJHWSQKIKGQMW-IQXANGCESA-N 0.000 claims 1
- URMNFQZBGGNUFW-GWUWNPHMSA-N (3r,4s)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-3-thiophen-3-yl-8-azabicyclo[3.2.1]octane Chemical compound C([C@@H]1C2CCC(C[C@H]1C1=CSC=C1)N2C)OC1=CC=CC(Cl)=C1Cl URMNFQZBGGNUFW-GWUWNPHMSA-N 0.000 claims 1
- RBNSYWDTFUKXQZ-FPGXKEGCSA-N (3r,4s)-8-methyl-4-(naphthalen-1-yloxymethyl)-3-thiophen-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@H]2[C@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CS1 RBNSYWDTFUKXQZ-FPGXKEGCSA-N 0.000 claims 1
- UMYJBBNRBNRSJQ-IITXJAJYSA-N (3r,4s)-8-methyl-4-(naphthalen-1-yloxymethyl)-3-thiophen-3-yl-8-azabicyclo[3.2.1]octane Chemical compound C=1([C@H]2[C@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)C=CSC=1 UMYJBBNRBNRSJQ-IITXJAJYSA-N 0.000 claims 1
- YHDKBTKAERDNPZ-SBEAFCBVSA-N (3s,4r)-3-(5-chlorofuran-2-yl)-4-[(2,3-difluorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1OC(Cl)=CC=1)N2C)OC1=CC=CC(F)=C1F YHDKBTKAERDNPZ-SBEAFCBVSA-N 0.000 claims 1
- HLVQGNMATJQJSU-SBEAFCBVSA-N (3s,4r)-3-(5-chlorothiophen-2-yl)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1SC(Cl)=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl HLVQGNMATJQJSU-SBEAFCBVSA-N 0.000 claims 1
- JXGVQQOIQCDFIK-CAQHPJOKSA-N (3s,4r)-3-(5-chlorothiophen-2-yl)-8-methyl-4-naphthalen-1-yl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](C3CCC(C2)N3C)C=2C3=CC=CC=C3C=CC=2)=CC=C(Cl)S1 JXGVQQOIQCDFIK-CAQHPJOKSA-N 0.000 claims 1
- WSMMRRHJYLDERV-JLHLRHAYSA-N (3s,4r)-3-(5-chlorothiophen-2-yl)-8-methyl-4-naphthalen-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](C3CCC(C2)N3C)C=2C=C3C=CC=CC3=CC=2)=CC=C(Cl)S1 WSMMRRHJYLDERV-JLHLRHAYSA-N 0.000 claims 1
- GBDJSNIQOSJLGD-PXMFUHLKSA-N (3s,4r)-3-(furan-2-yl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CO1 GBDJSNIQOSJLGD-PXMFUHLKSA-N 0.000 claims 1
- HMSARLHRQFZWRA-MOBXORJESA-N (3s,4r)-3-(furan-3-yl)-8-methyl-4-(naphthalen-1-yloxymethyl)-8-azabicyclo[3.2.1]octane Chemical compound C=1([C@@H]2[C@@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)C=COC=1 HMSARLHRQFZWRA-MOBXORJESA-N 0.000 claims 1
- MRHADVRVQLEMHB-IOSBVQAASA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-3-(5-methoxythiophen-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound S1C(OC)=CC=C1[C@@H]1[C@@H](COC=2C(=C(Cl)C=CC=2)Cl)C(N2C)CCC2C1 MRHADVRVQLEMHB-IOSBVQAASA-N 0.000 claims 1
- UXVCEUMUEPEJLI-IOSBVQAASA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-3-(furan-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1OC=CC=1)N2C)OC1=CC=CC(Cl)=C1Cl UXVCEUMUEPEJLI-IOSBVQAASA-N 0.000 claims 1
- IFELXXBSGKFFEI-GYMHETDLSA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-3-(furan-3-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C1=COC=C1)N2C)OC1=CC=CC(Cl)=C1Cl IFELXXBSGKFFEI-GYMHETDLSA-N 0.000 claims 1
- URMNFQZBGGNUFW-GYMHETDLSA-N (3s,4r)-4-[(2,3-dichlorophenoxy)methyl]-8-methyl-3-thiophen-3-yl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C1=CSC=C1)N2C)OC1=CC=CC(Cl)=C1Cl URMNFQZBGGNUFW-GYMHETDLSA-N 0.000 claims 1
- OBPNTZOWNNQBTD-IOSBVQAASA-N (3s,4r)-4-[(2,3-difluorophenoxy)methyl]-3-(5-methoxythiophen-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound S1C(OC)=CC=C1[C@@H]1[C@@H](COC=2C(=C(F)C=CC=2)F)C(N2C)CCC2C1 OBPNTZOWNNQBTD-IOSBVQAASA-N 0.000 claims 1
- ZIAVAISOXIFRTR-IOSBVQAASA-N (3s,4r)-4-[(2,3-difluorophenoxy)methyl]-3-(furan-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound C([C@H]1C2CCC(C[C@@H]1C=1OC=CC=1)N2C)OC1=CC=CC(F)=C1F ZIAVAISOXIFRTR-IOSBVQAASA-N 0.000 claims 1
- RIIDXAGXVAYGLA-VUROTCPHSA-N (3s,4r)-4-[(2,3-dimethoxyphenoxy)methyl]-3-(furan-2-yl)-8-methyl-8-azabicyclo[3.2.1]octane Chemical compound COC1=CC=CC(OC[C@@H]2[C@H](CC3CCC2N3C)C=2OC=CC=2)=C1OC RIIDXAGXVAYGLA-VUROTCPHSA-N 0.000 claims 1
- RBNSYWDTFUKXQZ-PXMFUHLKSA-N (3s,4r)-8-methyl-4-(naphthalen-1-yloxymethyl)-3-thiophen-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C1([C@@H]2[C@@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)=CC=CS1 RBNSYWDTFUKXQZ-PXMFUHLKSA-N 0.000 claims 1
- UMYJBBNRBNRSJQ-MOBXORJESA-N (3s,4r)-8-methyl-4-(naphthalen-1-yloxymethyl)-3-thiophen-3-yl-8-azabicyclo[3.2.1]octane Chemical compound C=1([C@@H]2[C@@H](COC=3C4=CC=CC=C4C=CC=3)C3CCC(C2)N3C)C=CSC=1 UMYJBBNRBNRSJQ-MOBXORJESA-N 0.000 claims 1
- YEWGKKFJKGOBIG-UHFFFAOYSA-N 1-thiophen-2-yl-8-azabicyclo[3.2.1]octane Chemical compound C1CCC(N2)CCC21C1=CC=CS1 YEWGKKFJKGOBIG-UHFFFAOYSA-N 0.000 claims 1
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 206010070606 Post stroke depression Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001561 neurotransmitter reuptake Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300213 | 2003-02-12 | ||
| US44810603P | 2003-02-20 | 2003-02-20 | |
| PCT/EP2004/050107 WO2004072071A1 (en) | 2003-02-12 | 2004-02-10 | 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006517568A JP2006517568A (ja) | 2006-07-27 |
| JP2006517568A5 true JP2006517568A5 (enExample) | 2011-01-27 |
Family
ID=32870667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006502018A Ceased JP2006517568A (ja) | 2003-02-12 | 2004-02-10 | ８−アザ−ビシクロ［３．２．１］オクタン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害薬として使用する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7247643B2 (enExample) |
| EP (1) | EP1594868B1 (enExample) |
| JP (1) | JP2006517568A (enExample) |
| AT (1) | ATE448223T1 (enExample) |
| AU (1) | AU2004212166B2 (enExample) |
| CA (1) | CA2515584A1 (enExample) |
| DE (1) | DE602004024033D1 (enExample) |
| DK (1) | DK1594868T3 (enExample) |
| ES (1) | ES2335664T3 (enExample) |
| MX (1) | MXPA05008314A (enExample) |
| NZ (1) | NZ541249A (enExample) |
| WO (1) | WO2004072071A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014114A2 (en) * | 2001-08-08 | 2003-02-20 | Neurosearch A/S | Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| EP1779851A1 (en) * | 2005-10-31 | 2007-05-02 | Boehringer Ingelheim Pharma GmbH & Co.KG | Treatment of diabetes |
| JP5194607B2 (ja) * | 2006-07-26 | 2013-05-08 | 大正製薬株式会社 | ソーシャルインターラクションの低下予防・改善剤 |
| DE102007046887A1 (de) * | 2007-09-28 | 2009-04-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von (1R,5S)-Anhydroecgoninestersalzen |
| WO2009065845A1 (en) * | 2007-11-20 | 2009-05-28 | Neurosearch A/S | A method for treating over-eating disorders |
| US8101642B2 (en) | 2008-06-05 | 2012-01-24 | Sk Biopharmaceuticals Co., Ltd. | 3-substituted propanamine compounds |
| US8546576B2 (en) | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
| WO2010086612A1 (en) | 2009-01-29 | 2010-08-05 | Cambrex Karlskoga Ab | Process for preparing enantiomerically enriched alkaloids |
| WO2014130910A1 (en) | 2013-02-22 | 2014-08-28 | Baylor College Of Medicine | Treatment for substance use disorders and stress disorders |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI111367B (fi) * | 1991-02-04 | 2003-07-15 | Aventis Pharma Inc | Menetelmä terapeuttisesti käyttökelpoisten N-(aryylioksialkyyli)heteroaryyli-8-atsabisyklo[3.2.1]oktaanijohdannaisten valmistamiseksi ja menetelmässä käytetyt välituotteet |
| AU672052B2 (en) * | 1992-12-23 | 1996-09-19 | Neurosearch A/S | Antidepressant and antiparkinsonian compounds |
| CZ285571B6 (cs) | 1995-11-02 | 1999-09-15 | Neurosearch A/S | Kondenzované tropanové deriváty, způsob jejich výroby, farmaceutické prostředky, které je obsahují a jejich použití k léčení |
| TR199801641T2 (xx) | 1996-02-22 | 1998-11-23 | Neurosearch A/S | Tropan t�revleri bunlar�n haz�rlanmas� ve kullan�m� |
| AU4819099A (en) | 1998-06-19 | 2000-01-05 | Eli Lilly And Company | Inhibition of serotonin reuptake |
| AU9543601A (en) * | 2000-10-13 | 2002-04-22 | Neurosearch As | Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| AU2002306848A1 (en) * | 2001-03-23 | 2002-10-08 | Elan Pharmaceuticals, Inc. | Methods of treating alzheimer's disease with piperidin derivates |
| JP2005508872A (ja) * | 2001-05-23 | 2005-04-07 | ニューロサーチ、アクティーゼルスカブ | トロパン誘導体及びこれをモノアミン神経伝達物質再取り込み阻害剤として使用する方法 |
| NZ529880A (en) * | 2001-07-06 | 2005-09-30 | Neurosearch As | Novel compounds, their preparation and use |
| WO2003014114A2 (en) * | 2001-08-08 | 2003-02-20 | Neurosearch A/S | Substituted amine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
-
2004
- 2004-02-10 JP JP2006502018A patent/JP2006517568A/ja not_active Ceased
- 2004-02-10 AT AT04709633T patent/ATE448223T1/de active
- 2004-02-10 ES ES04709633T patent/ES2335664T3/es not_active Expired - Lifetime
- 2004-02-10 DE DE602004024033T patent/DE602004024033D1/de not_active Expired - Lifetime
- 2004-02-10 AU AU2004212166A patent/AU2004212166B2/en not_active Ceased
- 2004-02-10 WO PCT/EP2004/050107 patent/WO2004072071A1/en not_active Ceased
- 2004-02-10 CA CA002515584A patent/CA2515584A1/en not_active Abandoned
- 2004-02-10 US US10/544,027 patent/US7247643B2/en not_active Expired - Fee Related
- 2004-02-10 MX MXPA05008314A patent/MXPA05008314A/es active IP Right Grant
- 2004-02-10 NZ NZ541249A patent/NZ541249A/en not_active IP Right Cessation
- 2004-02-10 EP EP04709633A patent/EP1594868B1/en not_active Expired - Lifetime
- 2004-02-10 DK DK04709633.4T patent/DK1594868T3/da active